Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many core safety statements align with the provided label excerpts (severe/life-threatening diarrhea; severe neutropenia; monitoring and withholding; loperamide/atropine). However, the response includes multiple label-inaccurate or unsupported specifics (e.g., boxed warning content, blood transfusions/growth factors, and several adverse reaction inclusions and efficacy claims) that are not supported by the supplied prescribing information text.
Category Scores
Accurate Statements
Onivyde (nal-IRI) is a liposomal encapsulation of irinotecan.
Drug/active ingredient section provided: Onivyde is irinotecan liposome injection / liposomal dispersion of irinotecan.
Onivyde is used in combination with fluorouracil and leucovorin.
Not provided in the supplied label excerpts for evaluation; however the claim is consistent with combination therapy wording typically associated with Onivyde. (No direct label excerpt provided in prompt.)
The most serious risks associated with Onivyde include severe diarrhea.
Warnings 5.2: "ONIVYDE can cause severe and life-threatening diarrhea."
The most serious risks associated with Onivyde include severe myelosuppression (low blood cell counts).
Warnings 5.1 describes severe neutropenia (a component of myelosuppression). Provided excerpt: "ONIVYDE can cause severe or life-threatening neutropenia..."
Diarrhea associated with Onivyde can be life-threatening.
Warnings 5.2: "severe and life-threatening diarrhea."
Myelosuppression associated with Onivyde can result in increased susceptibility to infections.
Warnings 5.1 describes severe/fatal neutropenic sepsis; while not explicitly phrased as "increased susceptibility to infections," the label indicates neutropenic sepsis risk.
Management of Onivyde side effects may involve dose modification or interruption.
Warnings 5.1 and 5.2 include "Withhold ONIVYDE" for neutropenia/diarrhea.
Management of Onivyde side effects may involve supportive care.
Warnings 5.2 includes specific supportive pharmacologic management: loperamide for late diarrhea; atropine for early diarrhea.
For diarrhea, anti-diarrheal medications are prescribed.
Warnings 5.2: "Administer loperamide for late diarrhea..."
Onivyde carries a Boxed Warning regarding the risks of diarrhea and myelosuppression.
Not directly supported by provided label excerpts. (No boxed warning text included in prompt excerpts.)
Patients receiving Onivyde must be monitored closely for diarrhea and myelosuppression.
Warnings 5.1 and 5.2 include monitoring blood cell counts periodically and withhold/resume guidance tied to neutropenia and diarrhea severity.
Onivyde can cause liver enzyme elevations.
Not supported by provided excerpts (only severe neutropenia and severe diarrhea, plus some administration/contraindication text are provided).
Patients receiving Onivyde should have liver function monitored.
Not supported by provided excerpts.
Regular monitoring of blood cell counts (complete blood count), electrolyte levels, and kidney function is essential during Onivyde treatment.
Partially supported: CBC monitoring is supported in 5.1. Electrolyte/kidney monitoring is not supported by the provided excerpts.
Overdose of irinotecan (the active component of Onivyde) can exacerbate known toxicities such as severe diarrhea and myelosuppression.
Not supported by provided label excerpts.
Unsupported Statements
Onivyde is used in combination with fluorouracil and leucovorin.
No indication/combination regimen text was included in the supplied label excerpts for evaluation.
The most serious risks associated with Onivyde include severe myelosuppression (low blood cell counts).
Label excerpt specifically addresses severe neutropenia; 'myelosuppression' and 'low blood cell counts' are broader than the provided label language.
Diarrhea can lead to dehydration, electrolyte imbalance, and kidney failure.
Not supported by the provided label excerpts.
Myelosuppression associated with Onivyde can result in bleeding.
Not supported by provided label excerpts.
Myelosuppression associated with Onivyde can result in anemia.
Not supported by provided label excerpts.
Common side effects reported in clinical trials for Onivyde when used in combination include fatigue.
Not supported by provided label excerpts.
Common side effects reported in clinical trials for Onivyde when used in combination include diarrhea.
While diarrhea is mentioned as common in the provided excerpt, the claim is not tied to the combination regimen in the excerpt. Also, 'common side effects ... include diarrhea' is only partially evidenced by the provided general statements.
Common side effects reported in clinical trials for Onivyde when used in combination include nausea.
Not supported by provided label excerpts.
Common side effects reported in clinical trials for Onivyde when used in combination include vomiting.
Not supported by provided label excerpts.
Common side effects reported in clinical trials for Onivyde when used in combination include decreased appetite.
Not supported by provided label excerpts.
Common side effects reported in clinical trials for Onivyde when used in combination include stomatitis (inflammation of the mouth).
Not supported by provided label excerpts.
Common side effects reported in clinical trials for Onivyde when used in combination include fever.
Not supported by provided label excerpts.
For myelosuppression, blood transfusions may be administered.
Not supported by provided label excerpts.
For myelosuppression, growth factors may be administered.
Not supported by provided label excerpts.
Onivyde carries a Boxed Warning regarding the risks of diarrhea and myelosuppression.
No boxed warning text was included in the supplied label excerpts for verification.
Patients with pre-existing liver impairment may be at increased risk for certain Onivyde side effects.
Not supported by provided label excerpts.
Elderly patients may be at increased risk for certain Onivyde side effects.
Not supported by provided label excerpts.
Onivyde may alter its pharmacokinetic profile compared to non-liposomal irinotecan.
Not supported by provided label excerpts.
Clinical trials have shown that Onivyde, in combination therapy, can improve overall survival compared to other treatment regimens in patients with metastatic pancreatic adenocarcinoma who have progressed on gemcitabine-based therapy.
No efficacy endpoints/overall survival statements were included in the supplied label excerpts.
Clinical trials have shown that Onivyde, in combination therapy, can improve progression-free survival compared to other treatment regimens in patients with metastatic pancreatic adenocarcinoma who have progressed on gemcitabine-based therapy.
No efficacy endpoints/progression-free survival statements were included in the supplied label excerpts.
Regular monitoring of blood cell counts (complete blood count), electrolyte levels, and kidney function is essential during Onivyde treatment.
CBC monitoring is supported (5.1). Electrolyte and kidney monitoring are not supported by provided excerpts.
Onivyde can cause liver enzyme elevations.
Not supported by provided label excerpts.
Patients receiving Onivyde should have liver function monitored.
Not supported by provided label excerpts.
Overdose of irinotecan (the active component of Onivyde) can exacerbate known toxicities such as severe diarrhea and myelosuppression.
No overdose section was included in the provided excerpts.
Contradictions
Low
AI Statement
For diarrhea, anti-diarrheal medications are prescribed.
Label Reference
Warnings 5.2
Important Omissions
Contraindication details: severe hypersensitivity/anaphylaxis to Onivyde or irinotecan HCl.
Importance:
Moderate
Specific withholding threshold language for neutropenia: withholding based on ANC <1500/mm3 or neutropenic fever, and monitoring on Days 1 and 8 of each cycle.
Importance:
Moderate
Specific diarrhea management thresholds: withhold for Grade 2-4 diarrhea; loperamide for late diarrhea; atropine for early diarrhea; and 'do not administer' in bowel obstruction.
Importance:
Moderate
Administration restriction: DO NOT SUBSTITUTE Onivyde for other irinotecan HCl-containing drugs.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related specifics (e.g., diarrhea causing kidney failure; transfusions/growth factors; liver impairment risk; elderly risk; boxed warning confirmation) are not supported by the provided label excerpts. While some core warnings (severe/life-threatening diarrhea and severe neutropenia with withholding and loperamide/atropine) are aligned, unsupported additions could mislead monitoring/management decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided prescribing-information excerpts (boxed warning text, specific side effects list, management steps like transfusions/growth factors, liver function impairment/elderly risk, and efficacy endpoints).
Suggested Improvement
Limit statements to the supplied label text (e.g., severe/life-threatening diarrhea; withholding based on diarrhea grade and neutropenia/ANC thresholds; loperamide for late diarrhea and atropine for early diarrhea; CBC monitoring on Days 1 and 8). Remove or qualify claims not evidenced in the provided excerpts, and ensure boxed warning language is verified from the label.